These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 22302014)

  • 1. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment.
    Rickels K; Shiovitz TM; Ramey TS; Weaver JJ; Knapp LE; Miceli JJ
    Int Clin Psychopharmacol; 2012 May; 27(3):142-50. PubMed ID: 22302014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine.
    Montgomery SA; Tobias K; Zornberg GL; Kasper S; Pande AC
    J Clin Psychiatry; 2006 May; 67(5):771-82. PubMed ID: 16841627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial.
    Kasper S; Herman B; Nivoli G; Van Ameringen M; Petralia A; Mandel FS; Baldinetti F; Bandelow B
    Int Clin Psychopharmacol; 2009 Mar; 24(2):87-96. PubMed ID: 21456104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative cost-analysis of initiating pregabalin or SSRI/SNRI therapy in benzodiazepine-resistant patients with generalized anxiety disorder in Spain.
    Carrasco JL; Álvarez E; Olivares JM; Rejas J
    Actas Esp Psiquiatr; 2013; 41(3):164-74. PubMed ID: 23803800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.
    Richard IH; McDermott MP; Kurlan R; Lyness JM; Como PG; Pearson N; Factor SA; Juncos J; Serrano Ramos C; Brodsky M; Manning C; Marsh L; Shulman L; Fernandez HH; Black KJ; Panisset M; Christine CW; Jiang W; Singer C; Horn S; Pfeiffer R; Rottenberg D; Slevin J; Elmer L; Press D; Hyson HC; McDonald W;
    Neurology; 2012 Apr; 78(16):1229-36. PubMed ID: 22496199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.
    Rickels K; Pollack MH; Feltner DE; Lydiard RB; Zimbroff DL; Bielski RJ; Tobias K; Brock JD; Zornberg GL; Pande AC
    Arch Gen Psychiatry; 2005 Sep; 62(9):1022-30. PubMed ID: 16143734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
    Silverstone PH; Salinas E
    J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial.
    Pollack MH; Zaninelli R; Goddard A; McCafferty JP; Bellew KM; Burnham DB; Iyengar MK
    J Clin Psychiatry; 2001 May; 62(5):350-7. PubMed ID: 11411817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of gastrointestinal symptom severity on response to venlafaxine extended-release in patients with generalized anxiety disorder.
    Lydiard RB; Pitrosky B; Hackett D; White C
    J Clin Psychiatry; 2004 Jun; 65(6):838-44. PubMed ID: 15291662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?
    Baldwin DS; Schweizer E; Xu Y; Lyndon G
    Eur Neuropsychopharmacol; 2012 Feb; 22(2):137-42. PubMed ID: 21839620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial.
    Alaka KJ; Noble W; Montejo A; Dueñas H; Munshi A; Strawn JR; Lenox-Smith A; Ahl J; Bidzan L; Dorn B; Ball S
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):978-86. PubMed ID: 24644106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.
    Davidson JR; DuPont RL; Hedges D; Haskins JT
    J Clin Psychiatry; 1999 Aug; 60(8):528-35. PubMed ID: 10485635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial.
    Hadley SJ; Mandel FS; Schweizer E
    J Psychopharmacol; 2012 Apr; 26(4):461-70. PubMed ID: 21693549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregabalin in generalized anxiety disorder: a placebo-controlled trial.
    Pande AC; Crockatt JG; Feltner DE; Janney CA; Smith WT; Weisler R; Londborg PD; Bielski RJ; Zimbroff DL; Davidson JR; Liu-Dumaw M
    Am J Psychiatry; 2003 Mar; 160(3):533-40. PubMed ID: 12611835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial.
    Hartford J; Kornstein S; Liebowitz M; Pigott T; Russell J; Detke M; Walker D; Ball S; Dunayevich E; Dinkel J; Erickson J
    Int Clin Psychopharmacol; 2007 May; 22(3):167-74. PubMed ID: 17414743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials.
    Rynn MA; Riddle MA; Yeung PP; Kunz NR
    Am J Psychiatry; 2007 Feb; 164(2):290-300. PubMed ID: 17267793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.
    Liebowitz MR; Gelenberg AJ; Munjack D
    Arch Gen Psychiatry; 2005 Feb; 62(2):190-8. PubMed ID: 15699296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
    Lam RW; Lönn SL; Despiégel N
    Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.